313 related articles for article (PubMed ID: 34272253)
21. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
22. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
[TBL] [Abstract][Full Text] [Related]
23. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab.
Benucci M; Damiani A; Infantino M; Manfredi M; Grossi V; Lari B; Gobbi FL; Sarzi-Puttini P
Immunol Res; 2021 Aug; 69(4):309-311. PubMed ID: 34324159
[No Abstract] [Full Text] [Related]
24. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
25. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Schulz E; Hodl I; Forstner P; Hatzl S; Sareban N; Moritz M; Fessler J; Dreo B; Uhl B; Url C; Grisold AJ; Khalil M; Kleinhappl B; Enzinger C; Stradner MH; Greinix HT; Schlenke P; Steinmetz I
Front Immunol; 2021; 12():803742. PubMed ID: 34950155
[TBL] [Abstract][Full Text] [Related]
26. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e167. PubMed ID: 34340982
[No Abstract] [Full Text] [Related]
27. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
McKenzie DR; Muñoz-Ruiz M; Monin L; Alaguthurai T; Lechmere T; Abdul-Jawad S; Graham C; Pollock E; Graham R; Sychowska K; Seow J; Tremain C; Gousis C; Domingo-Vila C; Cooper J; Vidler J; Owczarczyk K; Swampillai A; Kristeleit H; Malim MH; Fields P; Patten PEM; Papa S; North BV; Tree T; Doores KJ; Hayday AC; Irshad S
Cancer Cell; 2021 Nov; 39(11):1445-1447. PubMed ID: 34678151
[No Abstract] [Full Text] [Related]
28. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.
Rincon-Arevalo H; Choi M; Stefanski AL; Halleck F; Weber U; Szelinski F; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Potekhin A; Chen Y; Burmester GR; Eckardt KU; Guerra GM; Durek P; Heinrich F; Ferreira-Gomes M; Radbruch A; Budde K; Lino AC; Mashreghi MF; Schrezenmeier E; Dörner T
Sci Immunol; 2021 Jun; 6(60):. PubMed ID: 34131023
[TBL] [Abstract][Full Text] [Related]
29. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.
Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C
Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021.
Xu K; Dai L; Gao GF
Int Immunol; 2021 Sep; 33(10):529-540. PubMed ID: 34491327
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
Magliulo D; Wade SD; Kyttaris VC
Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
[TBL] [Abstract][Full Text] [Related]
32. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.
Speer C; Töllner M; Benning L; Klein K; Bartenschlager M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Morath C; Schmitt WH; Bergner R; Bartenschlager R; Schaier M
Ann Rheum Dis; 2022 Apr; 81(4):593-595. PubMed ID: 35012926
[No Abstract] [Full Text] [Related]
33. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: Comment.
Daungsupawong H; Wiwanitkit V
J Immunol Methods; 2024 Jun; 529():113671. PubMed ID: 38593868
[No Abstract] [Full Text] [Related]
34. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
Rimar D; Slobodin G; Paz A; Henig I; Zuckerman T
Ann Rheum Dis; 2021 Oct; 80(10):1354-1355. PubMed ID: 34049853
[No Abstract] [Full Text] [Related]
35. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
Bugatti S; De Stefano L; Balduzzi S; Greco MI; Luvaro T; Cassaniti I; Bogliolo L; Mazzucchelli I; D'Onofrio B; di Lernia M; Mauric E; Lilleri D; Baldanti F; Manzo A; Montecucco C
Ann Rheum Dis; 2021 Dec; 80(12):1635-1638. PubMed ID: 34172502
[No Abstract] [Full Text] [Related]
38. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
Siegel CA; Melmed GY; McGovern DP; Rai V; Krammer F; Rubin DT; Abreu MT; Dubinsky MC; ;
Gut; 2021 Apr; 70(4):635-640. PubMed ID: 33472895
[No Abstract] [Full Text] [Related]
39. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
Simader E; Tobudic S; Mandl P; Haslacher H; Perkmann T; Nothnagl T; Sautner J; Radner H; Winkler F; Burgmann H; Mrak D; Aletaha D; Winkler S; Blüml S
Ann Rheum Dis; 2022 Mar; 81(3):416-421. PubMed ID: 34844927
[TBL] [Abstract][Full Text] [Related]
40. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Chung SH; Wener M; Bays AM; Rahbar H; Morishima C; Bryan AB; Fink SL; Cohen S; Mani NS; Chaudhary A; Gardner GC
Ann Rheum Dis; 2021 Oct; 80(10):e165. PubMed ID: 34340981
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
